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Abstract
Purpose Drug interactions are of concern when treating
patients co-infected with human immunodeficiency virus
(HIV) and tuberculosis. Concomitant use of efavirenz
(EFV) with the enzyme inducer rifampicin might be
expected to increase EFV clearance. We investigated the
influence of concomitant tuberculosis treatment on the
plasma clearance of EFV.
Methods Fifty-eight patients were randomized to receive
their EFV-containing antiretroviral therapy either during or
after tuberculosis treatment. Steady-state EFV plasma
concentrations (n=209 samples) were measured, 83 in the
presence of rifampicin. Data were analyzed using a
non-linear mixed effects model, and the model was
evaluated using non-parametric bootstrap and visual
predictive checks.
Results The patients had a median age of 32 (range 19–55)
years and 43.1% were women. There was a bimodal
distribution of apparent clearance, with slow EFV
metabolizers accounting for 23.6% of the population
and having a metabolic capacity 36.4% of that of the
faster metabolizers. Apparent EFV clearance after oral
administration in fast metabolizers was 12.9 L/h/70 kg
whilst off tuberculosis treatment and 9.1 L/h/70 kg when
on tuberculosis treatment. In slow metabolizers, the
clearance estimates were 3.3 and 4.7 L/h/70 kg in the
presence and absence of TB treatment, respectively.
Overall there was a 29.5% reduction in EFV clearance
during tuberculosis treatment.
Conclusion Unexpectedly, concomitant rifampicin-containing
tuberculosis treatment reduced apparent EFV clearance
with a corresponding increase in EFV exposure. While
the reasons for this interaction require further investigation,
cytochrome P450 2B6 polymorphisms in the population
studied may provide some explanation.
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Introduction
Human immunodeficiency virus (HIV) and tuberculosis
co-infection is a serious public health issue in sub-Saharan
Africa. The World Health Organization has reported that in
South Africa, 53% of patients diagnosed with tuberculosis are
also HIV-positive [1]. When treating co-infected individuals,
determination of the optimal timing of antiretroviral therapy
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(ART) initiation in relation to tuberculosis treatment [2] is
complicated by the potential for clinically significant
drug–drug interactions [3].
Rifampicin, an important component of first-line
tuberculosis treatment, induces various hepatic cytochrome
P450 (CYP450) enzymes and may decrease plasma concen-
trations of antiretroviral (ARVs) sharing similar metabolic
pathways [4]. Conversely, isoniazid, also part of first-line
tuberculosis treatment, is a competitive inhibitor that
specifically targets enzymes CYP2C19 and CYP3A [5].
Efavirenz (EFV) is the preferred non-nucleoside reverse
transcriptase inhibitor (NNRTI) component of the first-line
ARV regimen in South Africa. Metabolism of EFV entails
8-hydroxylation by CYP2B6 with subsequent glucuronida-
tion [6, 7]. EFV is also known to induce CYP3A4 as well as
its own metabolism [8]. If EFV plasma concentrations are
decreased due to interaction with enzyme inducers, this may
increase the potential for therapeutic failure and the
development of drug resistance [9]. There are currently
conflicting reports in the literature regarding the nature of the
interaction, with some studies [10, 11] reporting increased
metabolism of EFV in the presence of rifampicin and others
reporting just the opposite [12, 13].
In order to better understand the interaction between
EFV and tuberculosis treatment, we designed the present
study in which a population–pharmacokinetics approach
was used to describe EFV clearance in South African
patients treated with rifampicin-containing first-line
tuberculosis regimens and NNRTI-based ART.
Methods
This study was conducted as part of the “Starting
Tuberculosis and Antiretroviral Therapy” (START) study,
an open label randomized clinical trial conducted in
Durban, South Africa between July 2006 and January
2008. All patients recruited to the START study were
ART naive, at least 18 years of age, and then received
both ART and standard first-line tuberculosis treatment in
a pre-existing directly observed therapy (DOT) program.
Only patients with no pre-defined laboratory abnormalities,
having received at least 10 but not more than 28 days of
tuberculosis treatment were enrolled. The standard tuber-
culosis treatment comprised rifampicin (R), isoniazid (H),
pyrazinamide (Z), and ethambutol (E) dosed daily on
weekdays only for 2 months, followed by R and H for a
minimum of 4 additional months. Patients weighing ≥50 kg
received five tablets daily of a fixed-dose combination
of RHZE containing 120/60/300/200 mg respectively,
followed by two tablets daily of RH 300/150 mg.
Patients weighing <50 kg received four tablets of the
RHZE 120/60/300/200 mg daily, followed by three
tablets of RH 150/100 mg. Women recruited to the
study were required to use both injectable progestogen
and barrier methods of contraception. All patients
received standard of care, which included multivitamins
and co-trimoxazole prophylaxis. No additional drugs
thought likely to interact with EFV were permitted.
Participants were randomized to receive both ART and
tuberculosis treatment simultaneously (integrated arm) or to
initiate ART only on completion of tuberculosis treatment
(sequential arm). In both arms, ART comprised once-daily
enteric-coated didanosine (400 mg for participants ≥60 kg;
250 mg for participants <60 kg), lamivudine 300 mg, and
EFV. Based on the expected interaction, when EFV was
administered in the presence of tuberculosis treatment,
participants weighing <50 kg received 600 mg and those
weighing ≥50 kg received 800 mg daily. After the
tuberculosis treatment was successfully completed, all
patients received EFV 600 mg. For patients in the
sequential arm, ART initiation occurred a median of 7 days
[interquartile range (IQR) 6–9 days] after TB treatment
completion. EFV concentrations were sampled at least
28 days after the TB treatment was completed; no residual
wash-out effects of the TB drugs were expected after this
time due to the short half-life of the TB drugs.
At enrolment and follow-up visits, demographic,
clinical, and treatment adherence data were collected.
Adherence to ART was determined by means of a
monthly pill count. Blood samples for trough EFV
plasma concentrations were obtained at the end of
months 1, 2, and 3 during tuberculosis treatment and at
the same time points after tuberculosis treatment was
successfully completed. The timing of blood sampling in
relation to EFV and tuberculosis treatment dosing was
recorded. Samples were drawn a median of 20.3 h post-dose
(IQR 14.8–25.2 h). Blood was collected in heparinized tubes,
which were stored on ice and separated at 3,000 rpm
within 1 h. Samples were then stored at −70°C until
analysis. Samples were analyzed in the Division of
Clinical Pharmacology, University of Cape Town. Plasma
EFV concentrations were determined using a modifica-
tion of a method by Chi et al. [14] based on liquid
chromatography/tandem mass spectrometry; the accuracy
ranged from 97.2 to 105.6%. Intraday and interday
precisions ranged from 1.3 to 4.6%. The lower limit of
quantitation (LLOQ) for EFV concentrations was 0.2 mg/L.
In five samples where the concentration was below the
LLOQ, the actual concentration was recorded for these
observations and used in the analysis. These concentrations
represent less than 3% of the data and were determined to be
unlikely to influence the final results.
Demographic and clinical data were analyzed using SAS
ver. 9.1 (SAS Institute, Cary, NC). Baseline characteristics
were compared using the Mann–Whitney, Fisher’s Exact or
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Student’s t test, as appropriate. A type 1 error (α) of 0.05
was used to reject the null hypothesis.
NONMEM (ver. VI 2.0), with the first-order conditional
estimation method and interaction option, was used [15]. A
one-compartment model with first-order absorption and
elimination was used to describe the data. The model was
parameterized in terms of absorption half-life, clearance,
and volume of distribution. The apparent clearance (CL/F)
after oral administration, where F is the bioavailability, was
estimated. As there were no EFV plasma concentrations in
the absorption phase, the absorption half-life was fixed to 1
h. Because EFV has a long elimination half-life and
measurements were made at steady state, there was no
reliable information on the volume of distribution (V/F).
Therefore, the V/F was fixed at 267 L/70 kg, as derived
from Csajka et al. ([16]. The population parameter
values were standardized for a body weight of 70 kg
using allometric scaling [CL/F = CL/FPOP × (weight/70)
0.75,
V/F = V/FPOP × (weight/70)] [17].
Sample times were classified as “occasions” (OCCs),
where OCCs 1, 2, and 3 represented EFV concentrations
sampled at the end of months 1, 2, and 3, respectively,
when EFV and tuberculosis treatment were co-administered
in the integrated arm. OCCs 4, 5, and 6 represented EFV
concentrations sampled once a month in each of the first
3 months after the completion of tuberculosis treatment in
both the integrated and sequential arms. The seemingly
random variability (between and within subjects) was
modeled as the exponent of the random effects, as
pharmacokinetic parameters resemble a log normal
distribution. Random residual variability was described
using a combined proportional and additive error model.
Using a step-wise model building process and subsequent
backward deletion, we identified covariates which had a
significant influence on CL/F. Mixture models with two
and three sub-populations for the distribution of CL/F
were evaluated. The statistical comparison of models
was based on the difference in the value of the
minimum objective function (ΔOBJ). ΔOBJ values are
approximately χ2 distributed, with degrees of freedom
equal to the difference in the number of parameters
between models. A ΔOBJ greater than minus twofold the
log-likelihood of the data was considered to be significant,
e.g. ΔOBJ of 3.84, α=0.05, 1df. The final model was
evaluated using non-parametric bootstrapping and visual
predictive checks.
The START study and this pharmacokinetic sub-study
were approved by the University of KwaZulu-Natal
Biomedical Research Ethics Committee (E183/04),
South African Medicines Control Council (20040969)
and were registered at ClinicalTrials.gov (NCT00091936).
Written informed consent was obtained from each study
participant.
Results
A total of 58 patients, randomized equally to either the
integrated or sequential treatment arm, were included in
the START pharmacokinetic sub-study. There were no
significant differences between the groups at baseline
(Table 1). Twenty-five patients received EFV 800 mg
during the integrated treatment. Mean monthly adherence
to ART in the integrated arm was 93.4% during and 87.1%
after the tuberculosis treatment. In the sequential arm,
mean monthly adherence to ART was 95.0%. There were
209 EFV plasma concentrations available for analysis
across six time points, 83 having been drawn during
concomitant EFV and tuberculosis treatment. Of the 29
patients in the integrated arm, 16 provided data on EFV
concentrations at all six time points, four were missing
data at one time point during tuberculosis treatment, seven
were missing data at one time point after tuberculosis
treatment, and four were unable to provide EFV data for
any of the time points after tuberculosis treatment. In the
sequential arm, 16 patients provided EFV data at three
time points, six provided data at two time points, three
provided data at one time point, and a further three
patients were unable to provide EFV data at any of the
time points. For one participant in the sequential arm, all
three time points were classified as BLD (below the limit
of detection). In total, there were six samples where the
EFV concentration was BLD. During and after TB
treatment, 55 and 62% of patients, respectively, had EFV
concentrations in the recommended range of 1–4 mg/L,
There were no serious EFV-related adverse effects, in any
patient with elevated EFV levels.
Of the available covariates investigated, sex, age,
serum transaminase levels, monthly EFV adherence,
baseline CD4 cell count, and baseline viral load did
not have a statistically significant effect on EFV
concentration. There was a large improvement in the
fit of the model when between-occasion variability in
CL/F was included. A further improvement in model
fit was achieved by assuming a bimodal distribution in
CL/F, dividing patients into slow and fast metabolizers
using a mixture model. There was no evidence for a
third sub-population in the CL/F distribution. The only
covariate that further improved the fit of the model
was the use of tuberculosis treatment. Stepwise back-
wards deletion (Table 2) confirmed the role of the covariates
in the final model.
Table 3 shows the final parameter estimates from the
original data and the non-parametric bootstrap analysis
(n=1,000). The bootstrap estimates are preferred because
they will be less influenced by outliers. As can be seen,
23.6% of the population were slow metabolizers with a
CL/F that was 36.4% that of the reference group (fast
Eur J Clin Pharmacol
metabolizers). The final model estimate for CL/F was
12.9 L/h/70 kg (95% confidence interval 11.1–15.2) in
fast metabolizers not on tuberculosis treatment. Concomitant
tuberculosis treatment reduced the overall EFV CL/F to
70.5% of the value without treatment. Based on these
estimates, the CL/F for fast metabolizers and slow metabo-
lizers on tuberculosis treatment is 9.1 and 3.3 L/h/70 kg,
respectively. For slow metabolizers not on tuberculosis
treatment, the CL/F was 4.7 L/h/70 kg. There was more
between-occasion variability in relative bioavailability
(43.5%) than between-subject variability (19.5%) in EFV
CL/F. Residual error in the final model was 11.9%
proportional and 0.47 mg/L additive error. The visual
predictive check of the final model, as shown in Fig. 1,
confirmed the adequacy of the model predictions.
Discussion
Although concomitant tuberculosis treatment was expected
to decrease EFV exposure by increasing apparent clearance,
the results of this study show that concomitant tuberculosis
treatment actually reduced EFV CL/F by 29.5%. The initial
expectation was based on the known ability of rifampicin to
induce CYP2B6 and CYP3A4 and hence to increase the
clearance of drugs that are substrates of these isoenzymes.
This has been borne out in a number of studies. For
example, in a group of 16 Italian patients, the mean CL/F of
EFV was found to be significantly higher in the
presence of concomitant tuberculosis treatment [11]. In
a group of 24 Spanish patients, median peak and trough
concentrations of EFV decreased by 24 and 18%,
respectively, when tuberculosis treatment was co-
administered [10]. In addition, a study of 19 Indian patients
found EFV CL/F to be slightly higher in the presence of
tuberculosis treatment [18]. As a result, various authors have
advocated increased doses of EFV in the presence of
tuberculosis treatment [19, 20]. Most recently, in silico
prediction of the EFV–R interaction utilizing model input
data from the literature (including weight and CYP2B6
phenotype) revealed 50 kg as the preferred weight cutoff for
EFV dose increment [21].
In contrast, there are reports that have challenged this
view. In a group of 20 black patients from South Africa,
despite wide inter-patient variability, the geometric mean
plasma concentrations of EFV were similar, whether or
not rifampicin was co-administered [13]. Two other
South African studies have also found that tuberculosis
treatment was not an important determinant of EFV
plasma concentrations [22, 23].
Table 1 Patient baseline characteristics
Variable Integrated arm (n=29) Sequential arm (n=29) P value
Median age in years (range) 32 (19–54) 32 (21–55) 0.45a
Females (%) 10 (34%) 15 (54%) 0.29b
Mean weight in kg (SD) 56.3 (7.8) 58.3 (9.9) 0.39a
Median body mass index in kg/m2 (range) 21.0 (16.9-28.2) 22.0 (16.3–33.6) 0.42c
Mean baseline CD4 count in cells/μL (SD) 281 (178) 276.2 (128) 0.71c
Median baseline viral load in copies/mL (range) 49200(503–843000) 419,00 (685–1,750,000) 0.62c
SD, Standard deviation
a Students t test
b Fishers exact test
cMann–Whitney test
Table 2 Model characteristics showing stepwise backwards deletion




1 Allometric scaling, between-occasion variability (BOV), tuberculosis treatment,
bimodal metabolic capacity (fast and slow metabolizers)
439.68 -
2 Allometric scaling, BOV, tuberculosis treatment 451.94 12.26
3 Allometric scaling, BOV, bimodal metabolic capacity (fast and slow metabolizers) 479.72 40.04
4 Allometric scaling, tuberculosis treatment, bimodal metabolic capacity
(fast and slow metabolizers)
1354.49 914.91
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Indirectly supporting our finding of a decreased
clearance is a case series describing nine patients, seven
of whom developed toxicity and required an EFV dose
reduction in the presence of tuberculosis treatment [12].
Of the nine patients described, eight were black patients of
African origin. Data from the Liverpool Therapeutic Drug
Monitoring registry also showed that the co-administration
of rifampicin and being black African were important
factors influencing EFV concentrations [24]. Without prior
adjustment for weight and ethnicity, EFV concentrations
were 48% higher when rifampicin was co-administered.
It should be noted that the earlier studies, showing an
increase in EFV clearance associated with rifampicin
co-administration, were all conducted in Caucasian
patients [10, 11, 18]
Higher EFV plasma concentrations in black Africans or
those of African descent have been associated with the
presence of a single nucleotide polymorphism, namely,
CYP2B6 516 G > T [25, 26] and CYP2B6c.983 T > C [27,
28]. In 74 Zimbabwean patients receiving no tuberculosis
treatment, EFV CL/F could be predicted by genotype, with
three groups of varying metabolic capacity [29]. More
recently, CYP2A6 has also been shown to independently
predict EFV concentrations, a finding that requires further
study [30]. Although genotype was not used as a covariate
in the present model, the separation of patients into “fast”
and “slow” metabolizers contributed to improving the fit of
the data. The estimate that 23.6% of the population studied
were slow metabolizers was similar to the slow metabolizer
genotype prevalence reported in other studies in black
African patients [23, 25, 29, 31]. Our model showed that
the capacity of the slow metabolizers was 36.4% that of the
fast metabolizers.
A Zimbabwean and West African study reported CL/F
values of 9.4 and 9.9 and 4.0 and 2.1 L/h in fast and slow
metabolizers, respectively [25, 29]. Our population estimate
of EFV CL/F was 12.9 L/h standardized for size 70 kg in
the fast metabolizers not on tuberculosis treatment. This is
similar to previously reported CL/F estimates in a series of
cohorts which have ranged from 9.4 to 11.7 L/h but without
weight scaling. Because this value is for fast metabolizers,
it is expected to be higher than other reported values which
did not distinguish these groups [16, 32-34].
In conclusion, this study demonstrated that, by reducing
clearance, concomitant tuberculosis treatment increased
EFV exposure in black African patients.












Fraction with slow clearance of EFV 0.227 32.9% 0.236 33.6% 0.105 0.413
Ratio of CL/F in slow metabolizers to CL/F in fast metabolizers 0.365 11.3% 0.364 13.4% 0.291 0.464
CL/F for EFV (L/h/70 kg) 12.8 7.50% 12.9 8.05% 11.1 15.2
Ratio of CL/F when taking TB treatment to CL/F without TB treatment 0.705 9.20% 0.705 9.6% 0.574 0.836
Proportional residual error 0.120 31.8% 0.119 43.0% 0.028 0.188
Additive residual error (mg/L) 0.462 26.8% 0.466 28.8% 0.221 0.755
Between-subject variability (CL/F) 0.215 36.5% 0.197 23.8% 0.091 0.278
Between-occasion variability in F 0.453 26.6% 0.435 19.5% 0.280 0.562
EFV, Efavirenz; CL/F, apparent clearance, where F is the bioavailability; TB, tuberculosis; RSE, relative standard error
Fig. 1 Visual predictive
check of model for efavirenz
concentrations. Right panel 5,
50, and 95 percentiles of
observations (gray lines with
symbols) and predictions
(black lines). Gray shading is
95% confidence interval for 5
and 95 percentile of predictions
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